-
Study aim
-
Oral nystatin prophylaxis in preventing Candida colonization
-
Design
-
A clinical trial with a control group, not blinded, randomized by random sequencing on 106 patients.
-
Settings and conduct
-
All infants born in Ayatollah Mousavi Hospital in Zanjan or admitted to other hospitals in the province who are in the first 72 hours of life and have a gestational age less than 32weeks or birth weight less than 1500gram , they enter one of the control or intervention groups and then, based on the prepared checklist, information about the variables is recorded and evaluated.
-
Participants/Inclusion and exclusion criteria
-
Infant born in the first 72 hours of life have a gestational age less than 32 weeks or a birth weight less than 1,500 grams will be examined after obtaining written and informed consent from the parents.Infants who have severe abnormalities or chromosomal abnormalities, severe sepsis, Congenital heart disease , Intraventricular hemorrage , disseminated intravascular coagulation ,trush ,diseases requiring surgery, fungal infections proven or parental disagreement are excluded from the study.
-
Intervention groups
-
Infants in the nystatin group receive 100,000 UI / ml, 0.5 ml intraorally and 0.5 ml via the urogastric tube three times a day from the nystatin oral suspension of Emad Darman Pars Company. The control group did not receive antifungal prophylaxis.
After one week, it is prepared from the oral and rectal mucosa by sterile swap method and sent to the laboratory for smear, culture and analysis.
-
Main outcome variables
-
Gestational age, birth weight,Type of delivery, prolonged premature rupture of the Membrane, use of broad-spectrum antibiotics , receiving invasive ventilation,Duration of receiving invasive ventilation,Oral culture and smear according to the candida, rectal culture and smear according to the candida,